Pancreatic Cancer Research

ResearcherNagoya University HospitalActive in the last 2 years

Kentaro Yamao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2497-7740; OpenAlex author ID A5041123163. Sources: OpenAlex.

Their work

Papers
27 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 3 papers · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 3 papers · 2024: 3 papers · 2025: 1 paper · 2026: 7 papers

Papers 27

  1. Pretreatment Contrast-Enhanced Harmonic EUS Predicts Pathological Response and Recurrence-Free Survival After Multimodal Treatment in Resectable Pancreatic Can… Co-author DOI 10.1002/jhbp.70180↗
  2. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Last author DOI 10.1007/s00535-025-02321-0↗
  3. Response to the letter to the editor regarding "Concealed pancreatic cancer in acute pancreatitis: Early MRCP and EUS surveillance improves prognosis and ident… Co-author DOI 10.1016/j.pan.2025.12.005↗
  4. From diagnostic technology to pathway design: what the Onomichi Method teaches us about early pancreatic cancer detection. Co-author DOI 10.1016/j.pan.2026.04.021↗
  5. Endoscopic ultrasound-guided fiducial marker placement for image-guided proton beam therapy in pancreatic cancer: implications for positional accuracy and posi… Co-author DOI 10.1093/jrr/rrag082↗
  6. Operator-rated puncture performance and first-pass lesion tissue area in pancreatic ductal adenocarcinoma: an exploratory single-center sub-analysis of endosco… Co-author DOI 10.21203/rs.3.rs-11273454/v1↗
  7. Utility of endoscopic ultrasonography elastography as a predictive tool for post-treatment recurrence of resectable pancreatic cancer treated with neoadjuvant … Co-author DOI 10.5946/ce.2025.414↗
  8. Concealed pancreatic cancer in acute pancreatitis: Early MRCP and EUS surveillance improves prognosis and identifies high-risk patients. Co-author DOI 10.1016/j.pan.2025.02.013↗
  9. Early diagnosis of pancreatic cancer via pancreatic juice cytology with a cell-block method in a patient with altered anatomy Co-author DOI 10.1055/a-2317-0520↗
  10. Endoscopic Ultrasound Can Differentiate High-Grade Pancreatic Intraepithelial Neoplasia, Small Pancreatic Ductal Adenocarcinoma, and Benign Stenosis. First author DOI 10.5009/gnl220521↗
  11. Impact of sarcopenia on biliary drainage during neoadjuvant therapy for pancreatic cancer. Co-author DOI 10.5946/ce.2022.278↗
  12. Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastatic pancreatic cancer: A randomiz… Co-author DOI 10.1002/jgh3.12966↗
  13. Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy. Co-author DOI 10.1007/s10147-023-02396-w↗
  14. Usefulness of Endoscopic Ultrasound Elastography and Contrast-Enhanced Endoscopic Ultrasound in the Diagnosis of Pancreatic Cancer of 10 mm or Less Co-author DOI 10.21203/rs.3.rs-3014153/v1↗
  15. Utility of contrast-enhanced harmonic EUS for diagnosis of portal vein invasion by pancreatic cancer. Co-author DOI 10.4103/eus-d-21-00185↗
  16. Improved detection of liver metastasis using Kupffer-phase imaging in contrast-enhanced harmonic EUS in patients with pancreatic cancer (with video). Co-author DOI 10.1016/j.gie.2020.06.051↗
  17. Analysis of Progression Time in Pancreatic Cancer including Carcinoma In Situ Based on Magnetic Resonance Cholangiopancreatography Findings. Co-author DOI 10.3390/diagnostics11101858↗
  18. Response to the Letter to the Editor 'Reply to "Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients T… Co-author DOI 10.2169/internalmedicine.3958-19↗
  19. Partial Pancreatic Parenchymal Atrophy Is a New Specific Finding to Diagnose Small Pancreatic Cancer (≤10 mm) Including Carcinoma in Situ: Comparison with Loca… Co-author DOI 10.3390/diagnostics10070445↗
  20. Contrast-enhanced harmonic endoscopic ultrasonography for evaluating the response to chemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.dld.2019.03.015↗
  21. Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrosp… Co-author DOI 10.2169/internalmedicine.2234-18↗
  22. Can Localized Stenosis of the Main Pancreatic Duct be a Predictive Factor for Early Detection of Pancreatic Cancer? First author DOI 10.5946/ce.2019.204↗
  23. Impact of avascular areas, as measured by contrast-enhanced harmonic EUS, on the accuracy of FNA for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.gie.2017.05.052↗
  24. Outcomes of endoscopic biliary drainage in pancreatic cancer patients with an indwelling gastroduodenal stent: a multicenter cohort study in West Japan. Co-author DOI 10.1016/j.gie.2018.01.021↗
  25. Alleviating Pancreatic Cancer-Associated Pain Using Endoscopic Ultrasound-Guided Neurolysis. Co-author DOI 10.3390/cancers10020050↗
  26. Association between the Risk Factors for Pancreatic Ductal Adenocarcinoma and Those for Malignant Intraductal Papillary Mucinous Neoplasm. Co-author DOI 10.1159/000481234↗
  27. Predictors of pain response in patients undergoing endoscopic ultrasound-guided neurolysis for abdominal pain caused by pancreatic cancer. Co-author DOI 10.1177/1756283x16644248↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masatoshi Kudo · 18 shared papers, 2016–2026 · strength 2.37
  2. Mamoru Takenaka · 16 shared papers, 2017–2026 · strength 2.13
  3. Takuya Ishikawa · 8 shared papers, 2023–2026 · strength 2.08
  4. Hiroki Kawashima · 7 shared papers, 2023–2026 · strength 1.86
  5. Tadashi Iida · 7 shared papers, 2023–2026 · strength 1.72
  6. Yasuyuki Mizutani · 7 shared papers, 2023–2026 · strength 1.72
  7. Kosuke Minaga · 15 shared papers, 2016–2025 · strength 1.66
  8. Yoshihisa Takada · 5 shared papers, 2025–2026 · strength 1.36
  9. Ken Kamata · 13 shared papers, 2016–2025 · strength 1.35
  10. Atsushi Nakai · 8 shared papers, 2017–2023 · strength 0.74
  11. Yuichi Kano · 2 shared papers, 2026 · strength 0.59
  12. Masayuki Kitano · 6 shared papers, 2016–2023 · strength 0.52
  13. Yasuo Otsuka · 3 shared papers, 2022–2024 · strength 0.52
  14. Takao Ohtsuka · 1 shared paper, 2026 · strength 0.50
  15. Hidekazu Tanaka · 4 shared papers, 2019–2023 · strength 0.46
  16. Kenji Yamao · 2 shared papers, 2024–2026 · strength 0.45
  17. Ippei Matsumoto · 5 shared papers, 2017–2022 · strength 0.45
  18. Eizaburo Ohno · 2 shared papers, 2023–2024 · strength 0.36
  19. Yoshifumi Takeyama · 4 shared papers, 2017–2022 · strength 0.33
  20. Masakatsu Tsurusaki · 3 shared papers, 2020–2021 · strength 0.32
  21. Kazunori Takeuchi · 1 shared paper, 2026 · strength 0.25
  22. Takeshi Yanagi · 1 shared paper, 2026 · strength 0.25
  23. Reiko Ashida · 1 shared paper, 2026 · strength 0.25
  24. Yukitaka Yamashita · 2 shared papers, 2018–2023 · strength 0.20
  25. Jun Nakahodo · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.